📰 Psychedelics News
Curated updates on microdosing, research, policy, and community.
Filters
RAND estimates millions of Americans microdosed psychedelics in 2025; New Jersey to commit $6 million to psilocybin research; new bills in New Hampshire and Iowa
Plus: Most Americans still feel neutral to negative about psychedelics, and New Mexico medical psilocybin program committees announced
Merry Prankster Tells Us About the Acid Tests, Kesey, and Vietnam
Ken Babbs opens up about ushering in psychedelic America. [...] Read More... The post Merry Prankster Tells Us About the Acid Tests, Kesey, and Vietnam appeared first on DoubleBlind Mag.
More than Medicine
Welcome to the Psychedelic Blog. I write about the impact of Psychedelics on Grieving, Relationships, Culture & Death.
Joshua White – Fireside Project and Lucy, an AI Training Simulator for Psychedelic Support
Fireside Project is a nonprofit that helps reduce the risks of psychedelic experiences through a free support line, coaching, education, and research. In this episode, Joshua White speaks with Psychedelics Today about...
Pα+ Psychedelic Bulletin #218: FDA’s Farchione Says Psychedelic INDs Are “a Third” of Her Workload; Ipsos/Psychedelic Alpha Poll; Reunion Eyes Single Phase 3 in PPD; America’s 10 Million Microdosers
FDA’s Farchione Says Psychedelic INDs Now “a Third” of Her Workload; NIDA’s Volkow Questions Schedule I Placement • Ipsos/Psychedelic Alpha Poll Probes Americans’ Attitudes Towards Psychedelics • RAND Estimates 10...
(Anti)prohibition, Psychonautics, and Designer Drugs
Alfredo Squillaro argues that informed use, drug checking, and education are far more effective than stigma and repression in reducing the risks of psychoactive substance use. The post (Anti)prohibition, Psychonautics...
Did New Jersey Really Just Legalize Psilocybin?
What S2283 Actually Does — and Why It Is a Research Pilot, Not Legalization In January 2026, the New Jersey Legislature passed Senate Bill S2283, formally titled the Psilocybin Behavioral Health Access and Services Ac...
Magic Yeast Is Another Way to Produce Psilocybin
Of course, Dr. K Mandrake and Virginia Haze have the tea. [...] Read More... The post Magic Yeast Is Another Way to Produce Psilocybin appeared first on DoubleBlind Mag.
Cannabis & Capitalism: Is Justice Possible in Legalization?
Join us for a critical examination of cannabis legalization's trajectory in the United States and abroad, from grassroots movement to corporatized industry.
Psychedelic Funding, Public Markets, and M&A in 2025
We have tracked every investment for the past ten years. Each year, we provide a review of the previous year’s psychedelics fundraising activity, public markets, and M&A. Here, we explore Q4 and full year 2025 via...
Discovering the Authentic Self Through Psychedelics
Oli Genn-Bash reflects on the Western pursuit of an “authentic self,” using personal psychedelic experiences to question whether self-discovery is less about uncovering a fixed identity and more about cultivating a he...
Press Release – Chacruna Launches 2026 Course on Diversity, Culture, and Social Justice in Psychedelics
The Chacruna Institute announces its nine-week live online course, Diversity, Culture, and Social Justice in Psychedelics (January–April 2026). The program explores intersectionality, equity, decolonial perspectives, ...
What to Watch Out For in the Psychedelic Sector in 2026
Ismail Lourido Ali, JD, Co-Executive Director of The Multidisciplinary Association for Psychedelic Studies (MAPS), offers thoughts on what to watch out for in the psychedelic sector in 2026. The post What to Watch Ou...
Op-Ed: Beyond Clinical Trials: Psychedelic-Assisted Therapy in Europe’s Real World
Helena Aicher, a researcher and psychotherapist working within Switzerland’s framework for limited medical use, reflects on how Europe’s psychedelics landscape evolved in 2025.
Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative
An industry wide look at how neuroplastogens are reshaping psychedelic medicine in 2026, with insights on Delix, AbbVie’s Gilgamesh acquisition, Enveric, and the shift toward nonhallucinogenic brain therapeutics. The ...